Novocure Selected as Technology Pioneer by World Economic Forum

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, was selected today as one
of the World Economic Forum’s “Technology Pioneers”, a recognition of
the world’s most innovative companies. Novocure is developing a novel,
proprietary therapy called TTFields for the treatment of solid tumor
cancers. TTFields is a low-toxicity anti-mitotic treatment that uses
low-intensity, intermediate frequency, alternating electric fields to
exert physical forces on key molecules inside cancer cells, disrupting
the basic machinery necessary for normal cell division, leading to
cancer cell death.

Novocure was chosen by a selection committee from among hundreds of
candidates as one of 49 companies. Thanks to its selection, the company
will have access to the one of the most influential and sought-after
business and political networks in the world, and be invited to the
World Economic Forum’s “Summer Davos” in Dalian, China, this September,
and the Annual Meeting in Davos in January.

“We’re glad to see an oncology company make it to the selection,” says
Fulvia Montresor, Head of Technology Pioneers at the World Economic
Forum. “Novocure is part of a group of entrepreneurs who are more aware
of the crucial challenges of the world around them, and who are
determined to do their part to solve those challenges with their
company.”

“Novocure’s selection by the World Economic Forum as a Technology
Pioneer recognizes the tremendous contributions to the field of oncology
of both Yoram Palti, MD, PhD, Novocure’s co-founder, professor emeritus
at the Technion Institute of Technnology, and the inventor of TTFields
therapy, and the Novocure team who transformed Palti’s idea into a
commercial stage product,” commented Bill Doyle, Novocure’s Executive
Chairman. “We believe TTFields will become an entirely new treatment
modality for a variety of solid tumor cancers and we are proud that the
World Economic Forum has recognized this important innovation.”

The Technology Pioneers were selected from among hundreds of applicants
by a selection committee of 68 academics, entrepreneurs, venture
capitalists and corporate executives. Notable members of the committee
include Arianna Huffington (founder, Huffington Post) and Henry Blodget
(editor-in-chief, Business Insider). The committee based its decisions
on criteria including innovation, potential impact, working prototype,
viability and leadership.

Past recipients include Google (2001), Wikimedia (2007), Mozilla (2007),
Kickstarter (2011) and Dropbox (2011). More information on past winners
can be found here.

About the World Economic Forum

The World Economic Forum is an international institution committed to
improving the state of the world through public-private cooperation in
the spirit of global citizenship. It engages with business, political,
academic and other leaders of society to shape global, regional and
industry agendas.

Incorporated as a not-for-profit foundation in 1971 and headquartered in
Geneva, Switzerland, the Forum is independent, impartial and not tied to
any interests. It cooperates closely with all leading international
organizations (www.weforum.org).

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) therapy is delivered by a portable,
non-invasive medical device designed for continuous use by patients. In
vitro
and in vivo studies have shown that TTFields therapy
slows and reverses tumor growth by inhibiting mitosis, the process by
which cells divide and replicate. TTFields therapy creates low
intensity, alternating electric fields within a tumor that exert
physical forces on electrically charged cellular components, preventing
the normal mitotic process and causing cancer cell death.

Approved Indication

The US FDA has approved the TTFields therapy delivery system, Optune
(previously known as the NovoTTF-100A System), for use as a treatment
for adult patients (22 years of age or older) with
histologically-confirmed GBM, following histologically or
radiologically-confirmed recurrence in the supra-tentorial region of the
brain after receiving chemotherapy. The device is intended to be used as
monotherapy, and is intended as an alternative to standard medical
therapy for GBM after surgical and radiation options have been
exhausted. Patients should only use Optune under the supervision of a
physician properly trained in use of the device. Full prescribing
information is available at www.optune.com/safety
or by calling toll free 1-855-281-9301.

About Novocure

Novocure is a private Jersey Isle oncology company pioneering a novel
therapy for solid tumors called TTFields. Novocure’s US operations are
based in Portsmouth, NH and New York, NY. Additionally, the company has
offices in Switzerland and Japan and a research center in Haifa, Israel.
For additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.

Contacts

Media and Investors:
Novocure
Ashley Cordova,
212-767-7558
acordova@novocure.com

Powered by WPeMatico